NCT00737113View on ClinicalTrials.gov

Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

December 31, 2013

Conditions
Allogeneic Stem Cell Transplantation
Interventions
DRUG

Genotropin (Recombinant Human Growth Hormone)

Patients will begin daily subcutaneous (SC) therapy at a starting dose of \~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.

Trial Locations (1)

27705

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Mitchell Horwitz, MD

OTHER